MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO) : vimarsana.com
LA JOLLA, Calif., April 02, 2024 -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the Standard Market of the Tokyo Stock Exchange , today announced that an...